CORD-19:e847d433e7424152a9846673209cb73027415ecd / 337709-337943 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/e847d433e7424152a9846673209cb73027415ecd","sourcedb":"CORD-19","sourceid":"e847d433e7424152a9846673209cb73027415ecd","text":"Of 152 p on dual NA therapy since at least 12 months, the majority receive zidovudine-lamivudine (30.3%) followed by lamivudine-stavudine (27%), zidovudine-didanosine (21.7%), didanosine-stavudine (13.8%), lamivudine-tenofovir (5.9%).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T3122","span":{"begin":0,"end":234},"obj":"Sentence"},{"id":"T82871","span":{"begin":0,"end":234},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T3122","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T82871","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T412","span":{"begin":0,"end":234},"obj":"Sentence"}],"attributes":[{"subj":"T412","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93c3ec","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ddec93"}]}]}}